Evidence map›Paper›PMID 29908326›Full record

ArticleNeurobiology of disease2018

Protein coding mitochondrial-targeted RNAs rescue mitochondrial disease in vivo.

Desiree M Markantone, Atif Towheed, Aaron T Crain, Jessica M Collins, Alicia M Celotto, Michael J Palladino

Open access · greenAbstract read
In one paragraph

Article in Neurobiology of disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Desiree M MarkantoneDepartment of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; Pittsburgh Institute for Neurodegenerative Diseases (PIND), University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Atif TowheedDepartment of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; Pittsburgh Institute for Neurodegenerative Diseases (PIND), University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Aaron T CrainDepartment of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; Pittsburgh Institute for Neurodegenerative Diseases (PIND), University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Jessica M CollinsDepartment of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; Pittsburgh Institute for Neurodegenerative Diseases (PIND), University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Alicia M CelottoDepartment of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; Pittsburgh Institute for Neurodegenerative Diseases (PIND), University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Michael J PalladinoDepartment of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; Pittsburgh Institute for Neurodegenerative Diseases (PIND), University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA. Electronic address: mjp44@pitt.edu.
Institute for Neurodegenerative Disorders · US

Funding

Pre-clinical studies of novel mitochondrial gene therapiesR01GM108073 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PALLADINO, MICHAEL JOHN · 2015 to 2018
$1.1M
Genetic modulation of mitochondrial functionR21AG059386 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PALLADINO, MICHAEL JOHN · 2018 to 2019
$430k
Mitochondrial RNA transport as a novel therapyR21NS078758 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PALLADINO, MICHAEL JOHN · 2012 to 2013
$410k
NIA NIH HHS R21 AG059386NIGMS NIH HHS R01 GM108073NINDS NIH HHS R21 NS078758
6 · The paper itself

Abstract

Mitochondrial encephalomyopathies (MEs) result from mutations in mitochondrial genes critical to oxidative phosphorylation. Severe and untreatable ME results from mutations affecting each endogenous mitochondrial encoded gene, including all 13 established protein coding genes. Effective techniques to manipulate mitochondrial genome are limited and targeted mitochondrial protein expression is currently unavailable. Here we report the development of a mitochondrial-targeted RNA expression (mtTRES) vector capable of protein expression within mitochondria (mtTRES

Indexed as

AnimalsAnimals, Genetically ModifiedCells, CulturedDrosophilaHeLa CellsHumansMitochondrial DiseasesMitochondrial ProteinsOpen Reading FramesRNA, MitochondrialMitochondrial ProteinsRNA, MitochondrialAllotopic RNA expressionDrosophilaMitochondrial encephalomyopathy (ME)Mitochondrial RNA import

Identifiers

PMID29908326
PMCPMC6082375
OpenAlexW2807867567

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.